IGC Pharma

IGC Pharma EV/FCF

The EV/FCF (Enterprise Value to Free Cash Flow) of IGC Pharma (IGC) as of Nov 12, 2026 is -4.13. In the previous year, EV/FCF (Enterprise Value to Free Cash Flow) was -4.62 — a change of -10.56% (higher).

EV/FCF

-4.13

YoY

-10.56%

Last updated:

EV/FCF (Enterprise Value to Free Cash Flow) of IGC Pharma is 2026 -4.13 . EV/FCF (Enterprise Value to Free Cash Flow) of IGC Pharma was 2025 -4.62 . It decreases by -10.56% higher compared to the previous year.

The IGC Pharma EV/FCF history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EV/FCF
Date
EV/FCF
Jan 1, 2019
0.30 USD
Jan 1, 2020
-0.97 USD
Jan 1, 2021
-0.89 USD
Jan 1, 2022
-1.78 USD
Jan 1, 2023
-2.83 USD
Jan 1, 2024
-4.14 USD
Jan 1, 2025
-4.62 USD
Jan 1, 2026
-4.13 USD
The IGC Pharma EV/FCF history
YEAREV/FCFYoY
-4.13-10.56%
-4.62+11.43%
-4.14+46.65%
-2.83+58.46%
-1.78+101.31%
-0.89-9.15%
-0.97-420.72%
0.30-102.58%
-11.77-26.91%
-16.11-82.56%
-92.39+804.11%
-10.22-30.47%
-14.70—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

IGC Pharma Stock analysis

What does IGC Pharma do? India Globalization Capital Inc. (IGC) is a Maryland-based company that focuses on the development, marketing, and sale of natural supplements, novel cannabis formulations, food and beverages, and the manufacturing of medical devices. IGC was established in 2005 and initially operated as a construction company in India. However, over the years, the company has evolved into a diversified company based in Maryland due to its innovative products and services. One of IGC's most well-known divisions is IGC Pharma, which focuses on cannabis-based medical formulations and medical devices. IGC holds patent applications for certain cannabis-based products and was one of the first companies to explore the use of cannabis as a potential treatment for Alzheimer's patients. In collaboration with the Institute for Medicine and the Origins of Infancy at the University of Maryland, IGC developed a novel THC-based medication for the treatment of spasms, pain, and other symptoms in multiple sclerosis patients. IGC has also developed the "Hyalolex" product, which is made from specific cannabinoids such as CBD. This preparation is available in Germany under the trade name "Cannabidiol Hexal." Hyalolex is available as a dietary supplement and has been proven effective in improving memory performance, attention, and cognitive abilities in Alzheimer's patients. IGC also operates the IGC Nutraceuticals division, which focuses on the manufacturing and marketing of high-quality natural products. These include vitamins, minerals, dietary supplements, and natural herbal supplements that promote physical and mental well-being and support healthy bodily processes. Some of IGC Nutraceuticals' products include Saffron for Depression Relief, the calcium and magnesium formulation, and Bharat Diagnostics. IGC will continue to invest in various fields, including cannabis-based pain relief, dementia treatments, electrochemical energy storage, and the manufacturing of devices that utilize natural resources such as coal and ore. Overall, IGC has become a diversified company that focuses on a variety of industries. IGC has been a pioneer in the cannabis industry and has gained a good reputation through innovative formulations and patents. By expanding into new industries and investing in new technologies, IGC will continue to stay at the forefront of innovation and strengthen its position as one of the emerging development companies in today's economy. IGC Pharma is one of the most popular companies on Eulerpool.

Frequently Asked Questions about IGC Pharma stock

EV/FCF (Enterprise Value to Free Cash Flow) of IGC Pharma is -4.13 in 2026.

EV/FCF (Enterprise Value to Free Cash Flow) of IGC Pharma changed from -4.62 to -4.13, representing a -10.56% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EV/FCF (Enterprise Value to Free Cash Flow) IGC Pharma since 2006 – with annual values, charts, and detailed analysis.

The EV/FCF ratio measures the enterprise value relative to free cash flow. It captures the true cash-generating ability of a business.

To evaluate EV/FCF (Enterprise Value to Free Cash Flow)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/FCF (Enterprise Value to Free Cash Flow).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/FCF (Enterprise Value to Free Cash Flow)'s IGC Pharma with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — IGC Pharma

All Key Metrics — IGC Pharma